酪氨酸激酶抑制剂治疗慢性髓性白血病的长期结局
综述总结了酪氨酸激酶抑制剂(TKI)治疗慢性髓性白血病(CML)的长期结局,涵盖13项随访5至14年的研究及多项短期研究。伊马替尼治疗25年证实其改善生存并可能治愈CML;第二代TKI起效更快、可识别伊马替尼耐药突变,但未较伊马替尼延长生存,且药物不良反应限制其广泛使用。尽管第二代TKI有其优势,伊马替尼因疗效和更优的安全性仍是CML的首选治疗。
要点
- 伊马替尼治疗25年证实改善生存并可能治愈CML。
- 第二代TKI起效快于伊马替尼并可识别伊马替尼耐药突变,但未较伊马替尼延长生存。
- 药物不良反应限制第二代TKI的广泛使用,而伊马替尼不良反应多为轻度。
核心结论
- 尽管第二代TKI有其优势,伊马替尼因疗效和更优的安全性仍是CML的首选治疗。
研究设计与样本
- 综述汇总13项随访5至14年的研究及多项新诊断慢性期CML的短期研究,并涉及德国、法国和英国3项学术试验。
主要发现
- 伊马替尼治疗25年证实对生存有益并可能治愈CML。
- 德国、法国和英国的3项学术试验未显示伊马替尼联合干扰素(IFN)的获益,尽管IFN具有免疫调节特性。
- 第二代TKI起效快于伊马替尼并可识别伊马替尼耐药突变,但与伊马替尼相比未延长生存。
- 药物不良反应限制第二代TKI的广泛使用,而伊马替尼不良反应频繁但多为轻度。
- 大型长期观察性研究显示,CML管理进展在多数但非全部情形下已惠及常规诊疗。
关键数值与推荐
- 欧洲治疗与结局研究长期生存评分考虑了多数CML患者死于其他原因这一事实。
- 已明确CML以外的生存决定因素,并关注合并症、转录本类型及高危附加染色体异常的负面影响。
临床怎么用
- 分子学监测疗效已确立,并成为其他肿瘤的范例。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Long-term outcomes with tyrosine kinase inhibitors (TKIs) show that their impact on chronic myeloid leukemia (CML) is sustained as shown by 13 studies with 5- to 14-year-follow-up, and numerous shorter-term studies of newly diagnosed chronic-phase CML. Twenty-five years of imatinib (IM) treatment confirm its beneficial effect on survival and possible cure of CML. Large, randomized, academic, treatment-optimization studies have confirmed and extended the pivotal International Randomized Study on Interferon and STI571. The 3 academic trials in Germany, France, and the United Kingdom did not show benefit of the IM-interferon (IFN) combination, despite the immunomodulatory properties of IFN. Second-generation (2G) TKIs induce responses faster than IM and recognize IM-resistance mutations but do not prolong survival compared with IM. Adverse drug-related reactions (ADRs) limit the general use of 2GTKIs despite frequent but mostly mild IM-ADRs. Molecular monitoring of treatment efficacy has been established serving as an example for other neoplasms. Comorbidities, transcript type, and the negative impact of high-risk additional chromosomal abnormalities were addressed. A new prognostic score (European Treatment and Outcome Study long-term survival score) accounts for the fact that the majority of patients with CML die of other causes. Non-CML determinants of survival have been identified. Large and long-term observational studies demonstrate that progress with CML management has also reached routine care in most but not all instances. Despite merits of 2GTKIs, IM remains the preferred treatment option for CML because of its efficacy and superior safety.
引用
- Guilhot F, Hehlmann R. Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia. Blood. 2025. PMID: 39486043. doi:10.1182/blood.2024026311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。